Introduction
============

Innate defense regulator-1 (IDR-1)[^4^](#FN5){ref-type="fn"} (KSRIVPAIPVSLL-NH~2~) is a synthetic peptide with no antimicrobial activity that enhances host bacterial infection control while suppressing harmful inflammation. Treatment of mice with IDR-1 provides protection from otherwise lethal infections with Gram-positive and Gram-negative pathogens, including methicillin-resistant *Staphylococcus aureus*, vancomycin-resistant *Enteroccocus*, and *Salmonella enterica* ([@B1]). In addition, IDR-1 enhances production of some monocyte-produced chemokines, including MCP-1 and RANTES (regulated on activation normal T cell expressed and secreted) and the anti-inflammatory cytokine interleukin-10. IDR-1 also suppresses production of Toll-like receptor-induced proinflammatory cytokines, including interleukin-6 and TNFα ([@B1]). Previously, the effects of IDR-1 were postulated to impact several intracellular pathways, including MAPK p38 and C/EBP, but the preceding molecular events remained unknown.

In this study, the cytoplasmic protein sequestosome-1 (p62) was identified as a molecular target of IDR-1. p62 is a multidomain scaffold (adaptor) protein, with many known interacting partners, including PKCζ ([@B2], [@B3]), p38 ([@B4]), RIP1 ([@B5]), and TRAF6 ([@B6]). p62 comprises an N-terminal PB1 domain that is primarily important for atypical PKC binding ([@B2]), a ZZ-type zinc finger (ZZ) domain that interacts with RIP1 ([@B5]), and a TRAF6 binding sequence domain recognized by TRAF6 ([@B6]). Additionally, a C-terminal ubiquitin-associated domain binds to polyubiquitin ([@B7]), a function recently demonstrated to facilitate the efficient activation of prosurvival and proapoptotic pathways by binding polyubiquitinated signaling proteins ([@B8]). The ubiquitin-associated domain is also considered the basis for the association between p62 and protein trafficking to the proteasome ([@B9], [@B10]). Thus, p62 functions as a nodal point in cellular signaling pathways, particularly in the regulation of NF-κB ([@B11], [@B12]) and cellular differentiation ([@B13]).

Here we provide evidence that IDR-1 specifically binds to the ZZ domain of p62. This binding event selectively stabilized TNFα-induced p62-RIP1 complex formation, but not TNFα-induced p62-PKCξ complex formation, and specifically modulated the downstream signaling pathways by activating MAPK p38 and C/EBPβ but not NF-κB. These studies provide new evidence for p62 as an important component of the immune system and demonstrate that IDR-1 can be used for the interrogation of the molecular events governing these innate responses.

EXPERIMENTAL PROCEDURES
=======================

Experimental Procedures are detailed in the [supplemental material](http://www.jbc.org/cgi/content/full/C109.073627/DC1).

RESULTS
=======

### 

#### p62 Is an Intracellular Target of IDR-1

We utilized stable isotope labeling by amino acids in cell culture (SILAC) and quantitative mass spectrometry-based proteomics to identify the major intracellular binding target of IDR-1. Murine leukemic RAW264.7 cells were grown in isotopically labeled medium (SILAC-heavy condition containing \[^13^C~6~\]arginine and \[^2^H~4~\]lysine) and in isotopically unlabeled medium (SILAC-light condition containing normal isotopic arginine and lysine) ([@B14]). The cells from both conditions were harvested, lysed, and subjected to affinity enrichment with desthiobiotinylated IDR-1 (heavy condition) or desthiobiotin alone (light, control condition) ([Fig. 1](#F1){ref-type="fig"}*A*). Proteins bound to the matrix after washing were eluted using free biotin, digested to peptides, and analyzed by liquid chromatography-tandem mass spectrometry. Quantitative SILAC ratios were then extracted after acquisition. Only two cellular proteins, p62 and XIAP-4, showed a marked and consistent differential binding to IDR-1 when compared with control in three repeat studies ([Fig. 1](#F1){ref-type="fig"}*B*). p62 was present with a specific/nonspecific (Sp:nSp) ratio approaching infinity indicating selective binding ([Fig. 1](#F1){ref-type="fig"}*C*, *right panel*). This analysis was confirmed using other, related IDR compounds, which detected only p62, but not XIAP-4, as the binding partner (not shown).

![**IDR-1 binds to sequestosome-1/p62.** *A*, schematic representation of the SILAC-proteomics approach utilized for the identification of the IDR-1 target. Streptavidin beads coated with desthiobiotinylated IDR-1 or desthiobiotin alone (negative control) were incubated with lysates prepared from SILAC-labeled and unlabeled RAW264.7 cells, respectively, followed by liquid chromatography-tandem mass spectrometry analysis of the combined bead eluent. Spectra derived from SILAC-labeled proteins and unlabeled proteins are presented as Sp and nSp. IDR-1 binding partners are identified by having an Sp:nSp ratio greater than 1. Proteins bound to the desthiobiotin control will produce Sp:nSp ratios close to or less than 1 and constitute background binders. *B*, proteins detected in the IDR-1 pulldown. Only proteins that were detected in more than one experiment are presented. p62 and XIAP-4 are highlighted by *lines. C*, IDR-1 interacts with p62. In the *left panel*, spectra from representative peptides of a non-specifically binding protein (GRP78) showed similar signals of the labeled (▲) and unlabeled (△) protein, *i.e.* the ratio of peak intensities of Sp over nSp is close to 1.0. In the *right panel*, spectra from representative peptides of p62 (SQSTM1) are observed only in the labeled condition, indicating the specific binding of p62 to IDR-1, *i.e.* the ratio of peak intensities of Sp over nSp is close to infinity. These data are representative of three replicate experiments. *D*, IDR-1 binds to human p62, but only weakly to XIAP. Lysates from HEK293T cells were pulled down against biocytin control (*C*) or biotinylated IDR-1 (*P*). Cell lysates are designated as (*L*) and were used as control. Proteins pulled down were immunoblotted with anti-p62 antibody (*left panel*) or with anti-XIAP antibody (*right panel*). *E*, IDR-1 binds to recombinant human p62 *in vitro*. Direct p62 binding by IDR-1 (●) or biocytin control (■) was determined using a plate coated with various concentrations of IDR-1. *Error bars* represent S.D.](zbc0031099740001){#F1}

To test direct binding of IDR-1 to human p62 and XIAP, lysates from HEK293T cells were incubated with streptavidin beads coated with biotinylated IDR-1 or biocytin as background control. Immunoblot analysis of the pulldown samples showed a strong band at ∼62 kDa that was detected with antibodies against p62 ([Fig. 1](#F1){ref-type="fig"}*D*, *left panel*). Densitometric analysis of this band revealed that it constitutes 64% of the intensity of p62 present in the cell lysate control, suggesting that the majority of the p62 from the lysate bound to the peptide. In contrast, the IDR-1 pulldown of the XIAP protein was very faint ([Fig. 1](#F1){ref-type="fig"}*D*, *right panel*) and constituted only 4% of the lysate control.

We next investigated direct IDR-1 binding to recombinant human p62. To test this, an *in vitro* protein binding assay using biotinylated IDR-1 and human recombinant glutathione *S*-transferase-labeled p62 was performed. As shown in [Fig. 1](#F1){ref-type="fig"}*E*, a concentration-dependent binding of p62 by IDR-1 was observed, whereas the control biocytin did not bind to p62 over the same concentration range. This binding was confirmed using a competitive binding experiment with biotinylated IDR-1 and unlabeled IDR-1 and with other IDR analogs in the same class (data not shown). These results confirmed direct binding of IDR-1 to the human p62 protein.

#### IDR-1 Binds to the ZZ Domain of p62

To determine which region of p62 is required for IDR-1 binding, FLAG-tagged human p62 deletion mutants ([Fig. 2](#F2){ref-type="fig"}*A*) were transfected into HEK293T cells and tested in biotinylated IDR-1 pulldown assays, as described above. Initially, the analysis was focused on the N-terminal, central, and C-terminal regions (constructs p62^1--117^, p62^118--440^, and p62^267--440^). IDR-1 did not bind to constructs p62^1--117^ and p62^267--440^, whereas it bound to p62^118--440^ ([Fig. 2](#F2){ref-type="fig"}*B*). Further, a p62 construct composed only of residues 118--266 (p62^118--266^) was also able to bind IDR-1. This central region of p62 (residues 118--266) is made up of three subdomains, including a ZZ (zinc finger) structural motif (residues 128--163), an intermediate domain LB (residues 170--220), and a TRAF6 binding region (residues 225--251). Successive deletions of each of these subdomains revealed that removal of residues 128--163 was sufficient to abolish IDR-1 binding, whereas deletion of LB or TRAF6 domains did not affect binding ([Fig. 2](#F2){ref-type="fig"}). These findings demonstrated that the ZZ domain of p62 is required for IDR-1 binding.

![**IDR-1 binds to the ZZ domain of p62.** *A*, schematic representation of the constructs used for mapping of the p62 domains that interact with IDR-1. *SH2*, an SH2 binding domain; *AID*, an acidic interaction domain (PB1 domain comprises the SH2 and AID); *LB*, LIM protein Ajuba binding domain; *PEST*, amino acids Pro, Glu, Ser, Thr-enriched domain; *LIR*, LC3-interacting region; *UBA*, ubiquitin-associated domain. *B*, analysis of IDR-1 pulldown assays with constructs presented in *A*. Lysates from HEK293T cells overexpressing FLAG-tagged deletion mutants of human p62 were pulled down against biocytin (*B*) or biotinylated IDR-1 (*P*). Cell lysates (*L*) were used as control. Proteins pulled down were immunoblotted with anti-FLAG antibody.](zbc0031099740002){#F2}

#### IDR-1 Selectively Affects p62 Complex Formation

The p62 protein is a critical signaling component that functions as a scaffold by forming multiple intracellular protein signaling complexes. Because IDR-1 bound to p62 directly, we investigated the consequences of this binding on intracellular p62 protein complex formation. Sanz *et al.* ([@B5], [@B6]) previously reported that TNFα receptor ligation stimulates complex formation between RIP1 and p62 via the ZZ domain of p62. Thus, we hypothesized that the p62-RIP1 complex formation might be affected in cells treated with IDR-1. In HEK293T cells overexpressing RIP1, IDR-1 induced an increase in TNFα-stimulated complex formation between RIP1 and p62 proteins ([Fig. 3](#F3){ref-type="fig"}*A*), suggesting that IDR-1 increased or stabilized this complex formation.

![**IDR-1 selectively affects intracellular p62 complex formation and signaling pathways.** *A*, IDR-1 enhances the p62 and RIP1 complex formation. HEK293T cells overexpressing RIP1 were stimulated with 100 ng/ml TNFα for 2 min with or without IDR-1 (200 μ[m]{.smallcaps}) pretreatment for 30 min. Lysates were immunoprecipitated (*IP*) with anti-p62 antibody and immunoblotted (*IB*) with anti-RIP1 and anti-p62 antibodies. *B*, IDR-1 has no effect on the p62 and PKCζ complex formation. HEK293T cells were stimulated with 100 ng/ml TNFα for 2 min with or without IDR-1 (200 μ[m]{.smallcaps}) pretreatment for 30 min. Lysates were immunoprecipitated with anti-PKCζ antibody and immunoblotted with anti-p62 and anti-PKCζ antibodies. *C*, IDR-1 treatment activates MAPK p38 in a p62-dependent manner. A549 cells were co-transfected with the PathDetect CHOP trans luciferase reporting system (Stratagene) for p38 activity and a p62 dominant-negative mutant (*DN*, p62^118--440^) or empty vector. 24 h after transfection, cells were untreated or treated with 200 μg/ml IDR-1, and p38 phosphorylation-dependent luciferase activity was analyzed. \*\*, *p* \< 0.01. The result is representative of an experiment repeated five times. *Error bars* represent S.D. in *C--E. D*, IDR-1 does not modulate NF-κB activity in a HEK293T NF-κB reporter cell line. Cells were pretreated with IDR-1 at 100 or 300 μg/ml, with or without 100 ng/ml TNFα stimulation. TNFα stimulation alone was used as control. Pretreatment with 100 or 300 μg/ml LL-37 prior to TNFα stimulation was used as a control for peptide modulation of NF-κB activity. *E*, treatment of A549 cells with IDR-1 induces C/EBPβ activity. Cells were treated with 200 μ[m]{.smallcaps} IDR-1 or with 100 ng/ml lipopolysaccharide (*LPS*), and C/EBPβ activity was detected by enzyme-linked immunosorbent assay. *F*, proposed model of IDR-1 mechanism of action via p62. IDR-1 binds to the ZZ domain on the p62 protein. This event results in stabilization of the intracellular complex with RIP1. IDR-1 interaction with p62 activates the p38 MAPK pathway, which results in activation of the transcription factor C/EBPβ. In the presence of TNFα stimulation, the NF-κB pathway is activated, although IDR-1 does not change complex formation with PKCζ nor, consequently, modulate NF-κB activity. Activation of transcriptional complexes results in modulation of cytokine/chemokine production in anti-infectious and inflammatory immune responses.](zbc0031099740003){#F3}

p62 interacts with PKCζ via its PB1 domain ([@B15]), distinct from the IDR-1 binding ZZ domain, and has been postulated as a molecular link between the atypical PKC-dependent NF-κB activation and the TNFα-RIP1 signaling axes ([@B5]). Therefore, the effect of IDR-1 on p62-PKCζ complex formation was also investigated. IDR-1 pretreated or untreated parental HEK293T cells were stimulated with TNFα followed by PKCζ immunoprecipitation. The amount of p62 co-immunoprecipitated with PKCζ was unaffected by IDR-1 treatment ([Fig. 3](#F3){ref-type="fig"}*B*), suggesting that IDR-1 does not alter the TNFα-induced complex formation between PKCζ and p62.

#### IDR-1 Selectively Affects Cellular Signaling Pathways

Complexes formed by p62 protein interactions regulate several intracellular signaling pathways ([@B10], [@B16]). Previously, independent studies have shown that p62 is involved in the p38 MAPK cascade ([@B4]) and that IDR-1-modulated cytokine production is linked to p38 ([@B1]). To investigate whether IDR-1 affects p38 MAPK signaling through p62, we utilized an approach based on a luciferase reporter of p38 activity and a dominant-negative mutant of p62 (p62^118--440^ cloned in pcDNA3.1) in the A549 epithelial cell line. IDR-1 treatment of these cells co-transfected with p38 activity reporter plasmids and an empty vector (pcDNA3.1) induced luciferase expression, indicating the activation of p38 ([Fig. 3](#F3){ref-type="fig"}*C*). This effect was abolished in cells co-transfected with the dominant-negative mutant of p62, suggesting that p38 activation by IDR-1 is mediated by p62.

The p62 protein has been reported to play a role in NF-κB activation by serving as a scaffold for PKCζ ([@B17]). Given the central role of NF-κB in cell signaling, we evaluated the effect of IDR-1 on NF-κB activity using a HEK293T NF-κB luciferase reporter cell line. The treatment of unstimulated cells with IDR-1 did not induce NF-κB activation, in contrast to the high NF-κB activation induced by TNFα stimulation ([Fig. 3](#F3){ref-type="fig"}*D*). Furthermore, pretreatment with IDR-1 did not alter the NF-κB activation by TNFα, whereas the cationic peptide LL-37 reduced NF-κB activity in a dose-dependent manner, as previously reported ([@B18]). These experiments were repeated in an A549 NF-κB luciferase reporter cell line with similar results (not shown).

Because NF-κB activity did not appear to be affected by IDR-1 treatment of cells, we investigated the IDR-1 effects on C/EBPβ given our previous findings of IDR-1 induction of this pathway ([@B1]) and the known role of p38 in the activation of the C/EBP family of transcription factors ([@B19], [@B20]). An induction of C/EBPβ activity at 30 and 60 min after IDR-1 treatment was observed in nuclear extracts of A549 cells assayed by C/EBPβ specific enzyme-linked immunosorbent assay ([Fig. 3](#F3){ref-type="fig"}*E*). These experiments confirm earlier findings ([@B1]) and indicate that C/EBPβ activity, but not NF-κB activity, is modulated by IDR-1 treatment of cells.

DISCUSSION
==========

The intracellular signaling network in host cells allows for efficient communication between the sensing of an incoming pathogen and the initiation of anti-infective responses. The p62 protein is emerging as one of the central signaling hubs of the cell, controlling this process ([@B8][@B9][@B10], [@B21]).

The data presented here demonstrate direct binding of IDR-1 to p62 and provide evidence that this binding has specific consequences on protein-protein interactions, as well as on downstream signaling pathways. p62 was discovered as the intracellular target of IDR-1 by an unbiased, non-hypothesis-driven proteomics approach. Due to high affinity of IDR-1 for p62, it is likely that p62 is the most physiologically relevant target. Although we identified XIAP-4 in the SILAC experiments, strong direct binding of IDR-1 to XIAP was not detected in human cell lysates, nor was binding to XIAP detected with other related IDR peptides that did bind p62. Another IDR-1 weak binding partner, glyceraldehyde 3-phosphate dehydrogenase, was also recently described ([@B22]).

Human p62 was confirmed as the IDR-1 target using binding assays and pulldown experiments from both endogenous and p62-overexpressing cell lysates. IDR-1 binding to both human and mouse p62, which share 99% amino acid sequence identity, was demonstrated. Through the investigation of p62 deletion mutants, we discovered that IDR-1 binds to the ZZ domain of p62, a zinc-binding protein interaction domain. Most compounds that act on protein-protein interactions antagonize or inhibit complex formation, but IDR-1 addition to cells led to a surprisingly specific effect; the TNFα-dependent receptor signaling complex of RIP1 and p62, which occurs at the ZZ domain, was stabilized, whereas the p62-PKCζ complex, which occurs at the PB1 domain proximal to the RIP1 binding region, was not affected.

The specific modulation of p62 signaling complexes by IDR-1 appears to have a corresponding effect on the downstream signaling. On one hand, p62 has been described as an activator of NF-κB due to its receptor-induced signaling complex formation with PKCζ ([@B11], [@B12]), but IDR-1 treatment did not modulate NF-κB activity downstream of TNFα, consistently with the p62-PKCζ complex formation being unaffected. On the other hand, p38 MAPK activation downstream of TNFα is regulated by RIP1 ([@B23]), and the increase of RIP1-p62 interaction by IDR-1 may explain the previously reported role of IDR-1 in p38-mediated signaling pathways ([@B1]). This is further strengthened by the observation that IDR-1-mediated activation of p38 is dependent on p62. The IDR-1-induced activation of C/EBPβ, downstream of p38, is also consistent with these and previous findings. Thus, we propose that the specific effects on intracellular signaling presented here contribute to the previously described IDR-1-modulated cytokine profile ([Fig. 3](#F3){ref-type="fig"}*F*).

IDR-1 has been demonstrated to prevent and treat infections and reduce associated inflammation ([@B1]). In addition, recent studies report that p62 expression contributes to regulating macrophage-mediated ([@B21]) and cancer-associated inflammation ([@B11], [@B16], [@B24]), raising the question as to whether IDR-1 might also affect inflammatory responses in the absence of pathogen stimulation. The discovery that p62 is the target of IDR-1 highlights the importance of p62 in innate immunity and reveals p62 as a potential therapeutic target for anti-infective therapy without induction of harmful inflammation, and conversely, potential anti-inflammatory therapy with added anti-infective function.
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